SV Health Investors Closes on New Venture Capital Fund, at $400M

In conjunction with the rebranding announcement, SV Health Investors, a Boston, MA-based venture capital and growth equity firm (fka SV Life Sciences), closed on its sixth flagship fund, at $400m.

SV VI, like the prior SV funds, will have a multi-sector focus and will invest in and support early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity opportunities with healthcare services and digital health companies.

SV also manages the Dementia Discovery Fund, plus five other funds that aim to support entrepreneurs and companies that create and deliver innovative treatments and healthcare solutions. Together, the seven funds have had capital commitments of more than $2 billion. Over the past 20 years, the firm has invested in over 175 companies adding more than 10 new portfolio companies in the past year.

SV Health Investors also has offices in London and San Francisco.



Join the discussion